Abstract
In the setting of increasing resistance in the causative agents of bacterial infections, the choice of antibiotics requires a highly responsible approach. The reasons for this are both achieving a reliable effect and preventing further spread of resistance.
Current reviews of resistance are an essential basis for empirical administration, optimally followed by identification and susceptibility testing of a particular pathogen for targeted therapy. The selection of appropriate drugs for treating community-acquired infections (urinary infections) should respect national guidelines, and the treatment of hospital-acquired infections should be adapted to local epidemiological conditions.
Several drugs have recently shown promise in treating infections caused by multiresistant microorganisms (ceftolozane/tazobactam, ceftazidime/avibactam, pivmecillinam).